ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1558

Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Abstract Number: 1860

Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients
Abstract Number: 0247

Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
Abstract Number: 0081

Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Abstract Number: 1819

Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
Abstract Number: 0645

Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Abstract Number: 0055

Time Course of Intestinal Permeability and Intestinal Inflammation in Rat Adjuvant-induced Arthritis
Abstract Number: 0721

Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis
Abstract Number: 0641

Title: EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Updated Results of Quit Connect Dissemination
Abstract Number: 0087

TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Abstract Number: 0477

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
Abstract Number: 1834

To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Abstract Number: 0193

Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, Double Blind, Placebo-controlled Phase II Study
Abstract Number: 1878

Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Abstract Number: 1413

Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].